PHASEBIO PHARMACEUTICALS INC's ticker is PHAS and the CUSIP is 717224109. A total of 59 filers reported holding PHASEBIO PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $1,169,000 | -70.7% | 6,643,702 | 0.0% | 0.06% | -71.7% |
| Q2 2022 | $3,986,000 | -54.5% | 6,643,702 | 0.0% | 0.20% | -19.0% |
| Q1 2022 | $8,770,000 | -49.4% | 6,643,702 | -0.0% | 0.25% | -27.7% |
| Q4 2021 | $17,340,000 | -16.1% | 6,643,704 | 0.0% | 0.35% | +42.9% |
| Q3 2021 | $20,662,000 | -16.4% | 6,643,704 | 0.0% | 0.24% | -23.9% |
| Q2 2021 | $24,715,000 | +7.5% | 6,643,704 | 0.0% | 0.32% | -37.6% |
| Q1 2021 | $22,987,000 | +3.0% | 6,643,704 | 0.0% | 0.52% | -12.4% |
| Q4 2020 | $22,323,000 | -4.3% | 6,643,704 | 0.0% | 0.59% | -40.3% |
| Q3 2020 | $23,319,000 | -23.7% | 6,643,704 | 0.0% | 0.99% | -19.7% |
| Q2 2020 | $30,561,000 | +39.0% | 6,643,704 | 0.0% | 1.23% | +7.0% |
| Q1 2020 | $21,991,000 | -45.8% | 6,643,704 | 0.0% | 1.15% | -40.2% |
| Q4 2019 | $40,593,000 | +46.5% | 6,643,704 | 0.0% | 1.92% | -16.3% |
| Q3 2019 | $27,704,000 | -68.2% | 6,643,704 | 0.0% | 2.29% | -62.4% |
| Q2 2019 | $87,165,000 | – | 6,643,704 | – | 6.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Johnson & Johnson Innovation - JJDC, Inc. | 1,607,044 | $5,400,000 | 0.70% |
| NEA Management Company, LLC | 6,643,704 | $22,323,000 | 0.59% |
| DAFNA Capital Management LLC | 320,542 | $1,077,000 | 0.32% |
| Platform Technology Partners | 141,025 | $474,000 | 0.23% |
| Parkman Healthcare Partners LLC | 110,547 | $371,000 | 0.10% |
| Rock Springs Capital Management LP | 1,314,374 | $4,416,000 | 0.09% |
| GSA CAPITAL PARTNERS LLP | 140,341 | $472,000 | 0.08% |
| SABBY MANAGEMENT, LLC | 65,000 | $218,000 | 0.04% |
| Virtu Financial LLC | 28,821 | $97,000 | 0.01% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 127,600 | $429,000 | 0.01% |